Aptabio Obtains Canadian Patent for Non-Alcoholic Steatohepatitis Treatment
[Asia Economy Reporter Lee Gwan-joo] Aptabio announced on the 22nd that it has obtained a Canadian patent for its non-alcoholic steatohepatitis (NASH) treatment 'APX-311'.
'APX-311' is a NASH treatment based on the 'NOX inhibitor discovery platform' and is planned to enter Phase 2 clinical trials this year. Aptabio has previously secured patents in Russia, Australia, Japan, the United States, and Mexico.
NASH is a disease in which fat accumulates in the liver and inflammation occurs due to poor lifestyle habits such as a high-fat diet and lack of exercise, regardless of alcohol consumption. One in five patients develops cirrhosis (fibrosis) or liver cancer. However, unlike hepatitis B and C, there is currently no adequate treatment available.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "While Others Rest, Nearly 3 Million May Work Substitute Public Holidays Without Extra Pay"
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
An Aptabio official stated, "We have been steadily obtaining patents in major countries to enhance the value of the NASH treatment," adding, "We plan to evaluate the efficacy and safety of the treatment through entry into Phase 2 clinical trials this year."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
